Algernon Pharmaceuticals Algernon Pharmaceuticals
  • Home
  • About Us
    • History & Overview
    • Management
    • Board of Directors
    • Medical and Scientific Advisory Board
    • Business Advisory Board
    • Corporate Presentation
    • Corporate Fact Sheet
  • Our Approach
    • Key Advantages
    • Pipeline
    • Targeted Diseases
      • Stroke
      • Chronic Cough
      • IPF
      • CKD
  • Investors
  • Media
  • Contact Us
Search

Presentations

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Annual General Meeting
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGN0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Company Info

  • Overview
  • Management Team
  • Presentations
  • Contacts
  • FAQ
October 30, 2022

Algernon Pharma - October 2022

October 26, 2022

Corporate Fact Sheet October 26, 2022

rss_feed RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.
Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals Inc. - All Rights Reserved
Close

Hit enter to search or ESC to close

Algernon Pharmaceuticals Inc.
  • Home
  • About Us
    • History & Overview
    • Management
    • Board of Directors
    • Medical and Scientific Advisory Board
    • Business Advisory Board
    • Corporate Presentation
    • Corporate Fact Sheet
  • Our Approach
    • Key Advantages
    • Pipeline
      • NP-120 (Ifenprodil)
      • AP-188 (DMT)
        • DMT- Stroke Program
        • DMT Background
        • Algernon’s DMT Research Plan
        • Pathway to Clinical Trials
        • Stroke Program Consultants
        • Manufacturing, CRO’s and IP
    • Targeted Diseases
      • Stroke
      • Chronic Cough
      • IPF
  • Investors & Media
    • News Releases
    • Investor Resources
      • CSE: AGN | OTCQB: AGNPF | XFRA: AGW0
      • Filings
      • FAQ
      • Investor Relations
      • Analyst Coverage
      • Annual Meeting Materials
    • Media
    • Upcoming Events
  • Contact Us